A new opioid-free pain medication was approved by the U.S. Food and Drug Administration (FDA) on Thursday, marking a non-addictive alternative for patients. Journavx (suzetrigine), made by Vertex ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

The FDA approved Journavx on Thursday following a pair of clinical trials on 874 participants with moderate to severe acute pain following abdominoplasty — commonly known as a "tummy tuck ...

The US FDA has approved Journavx, a new pain reliever without the risks for addiction or overdose linked to drugs like Vicodin and OxyContin.

Journavx is one of three recently approved drugs in Vertex Pharmaceuticals' product lineup. The U.S. Food and Drug Administration (FDA) approved suzetrigine under the brand name Journavx on Jan ...

The United States Food and Drug Administration (FDA) has approved a new non-opioid prescription medication, Journavx (suzetrigine), for adults with moderate to severe acute pain. Developed by ...

The use of Journavx for moderate to severe pain has not been studied beyond 14 days. The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to ...

AlgoTherapeutix blames a “strong placebo effect” for the mid-stage failure for its pain gel ATX01, but the company still ...

Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business. Vertex ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of ...

(NASDAQ:VRTX) has recently achieved a significant milestone with the FDA's approval of JOURNAVX(suzetrigine), a novel ...